Strong, near-complete functional inhibition accompanies more pronounced reductions in apoB and remnant cholesterol, yielding sizable decreases in CAD risk; mild “weak inhibition” corresponding to common variants may mainly lower TG, with less evident benefits on clinical endpoints. This evidence concerns the gene APOB and coronary artery disorder.